ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

States Sue Bristol-Myers Alleging Firm Took Illegal Actions To Block Taxol Competitors

June 7, 2002

Mass. Passes Tobacco Tax, ACS Lauds Victory Over Cigarette Industry

November 20, 1992

ACS Awards Grants To Wisconsin, USC For Behavior Research

July 16, 1993

Artificial Neural Networks Predict Clinical Outcomes

November 26, 2004

Barbara Rimer and Owen Witte To Be Named Members Of the President’s Cancer Panel

December 9, 2011

In Brief: Hammer Okay, Panel’s Pittsburgh Meeting Rescheduled For Oc 23; Campbell Leaves AICR

July 17, 1987